A Phase III, Randomized, Multicenter, Parallel-group, Non-inferiority Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Dolutegravir Plus Lamivudine in HIV-1 Infected Adults Who Are Virologically Suppressed
Phase of Trial: Phase III
Latest Information Update: 04 Dec 2018
At a glance
- Drugs Dolutegravir/lamivudine (Primary) ; Tenofovir alafenamide
- Indications HIV-1 infections
- Focus Registrational; Therapeutic Use
- Acronyms TANGO
- Sponsors ViiV Healthcare
- 26 Nov 2018 Planned End Date changed from 31 Jan 2021 to 22 Jul 2022.
- 26 Nov 2018 Status changed from active, no longer recruiting to recruiting.
- 31 Aug 2018 Biomarkers information updated